Generic placeholder image

Current Cardiology Reviews


ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Review Article

Role of β -blockers in Preventing Heart Failure and Major Adverse Cardiac Events Post Myocardial Infarction

Author(s): Nishant Johri*, Prithpal S. Matreja, Aditya Maurya, Shivani Varshney and Smritigandha

Volume 19, Issue 4, 2023

Published on: 01 March, 2023

Article ID: e110123212591 Pages: 8

DOI: 10.2174/1573403X19666230111143901

Price: $65


β-blockers have been widely utilized as a part of acute myocardial infarction (AMI) treatment for the past 40 years. Patients receiving β-adrenergic blockers for an extended period following myocardial infarction have a higher chance of surviving. Although many patients benefited from β-blockers, many do not, including those with myocardial infarction, left ventricle dysfunction, chronic pulmonary disease, and elderly people. In individuals with the post-acute coronary syndrome and normal left ventricular ejection fraction (LVEF), the appropriate duration of betablocker therapy is still unknown. There is also no time limit for those without angina and those who do not need β-blockers for arrhythmia or hypertension. Interestingly, β-blockers have been prescribed for more than four decades. The novel mechanism of action on cellular compartments has been found continually, which opens a new way for their potential application in cardiac failure and other cardiac events like post-myocardial infarction. Here, in this review, we studied β-blocker usage in these circumstances and the current recommendations for β-blocker use from clinical practice guidelines.

Keywords: Cardiovascular disease, HFrEF, CAD, LVEF, AMI, IHD.

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy